HAE Haemonetics Corp

Price (delayed)

$70.22

Market cap

$3.58B

P/E Ratio

55.29

Dividend/share

N/A

EPS

$1.27

Enterprise value

$4.19B

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of ...

Highlights
The price to earnings (P/E) is 65% lower than the 5-year quarterly average of 155.8
The company's quick ratio rose by 31% YoY and by 6% QoQ
The equity is up by 11% year-on-year but it has declined by 7% since the previous quarter
The company's gross profit fell by 9% YoY but it rose by 4.5% QoQ
The debt is up by 48% year-on-year and by 11% since the previous quarter
The company's EPS fell by 33% YoY and by 19% QoQ

Key stats

What are the main financial stats of HAE
Market
Shares outstanding
51.03M
Market cap
$3.58B
Enterprise value
$4.19B
Valuations
Price to earnings (P/E)
55.29
Price to book (P/B)
5.28
Price to sales (P/S)
3.96
EV/EBIT
52.81
EV/EBITDA
24.96
EV/Sales
4.64
Earnings
Revenue
$903.41M
EBIT
$79.42M
EBITDA
$168.02M
Free cash flow
$54.03M
Per share
EPS
$1.27
Free cash flow per share
$1.06
Book value per share
$13.29
Revenue per share
$17.74
TBVPS
$19.12
Balance sheet
Total assets
$1.79B
Total liabilities
$1.12B
Debt
$784.37M
Equity
$677.08M
Working capital
$456.03M
Liquidity
Debt to equity
1.16
Current ratio
3
Quick ratio
1.34
Net debt/EBITDA
3.64
Margins
EBITDA margin
18.6%
Gross margin
46%
Net margin
7.1%
Operating margin
8.8%
Efficiency
Return on assets
4.1%
Return on equity
9.2%
Return on invested capital
7.2%
Return on capital employed
5.1%
Return on sales
8.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
2.77%
1 week
4.08%
1 month
18.43%
1 year
-16.09%
YTD
-40.87%
QTD
5.37%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$903.41M
Gross profit
$415.89M
Operating income
$79.42M
Net income
$64.49M
Gross margin
46%
Net margin
7.1%
The operating income is down by 38% year-on-year and by 12% since the previous quarter
The operating margin has contracted by 35% YoY and by 15% from the previous quarter
HAE's net income is down by 32% year-on-year and by 19% since the previous quarter
The net margin is down by 30% year-on-year and by 22% since the previous quarter

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
P/E
55.29
P/B
5.28
P/S
3.96
EV/EBIT
52.81
EV/EBITDA
24.96
EV/Sales
4.64
The price to earnings (P/E) is 65% lower than the 5-year quarterly average of 155.8
The company's EPS fell by 33% YoY and by 19% QoQ
The price to book (P/B) is 23% lower than the last 4 quarters average of 6.9 and 18% lower than the 5-year quarterly average of 6.4
The equity is up by 11% year-on-year but it has declined by 7% since the previous quarter
The stock's P/S is 28% less than its last 4 quarters average of 5.5 and 12% less than its 5-year quarterly average of 4.5
The revenue fell by 4.5% YoY but it rose by 3.8% QoQ

Efficiency

How efficient is Haemonetics business performance
The company's return on invested capital fell by 49% YoY and by 20% QoQ
The company's return on assets fell by 45% YoY and by 23% QoQ
HAE's return on equity is down by 43% year-on-year and by 21% since the previous quarter
The company's return on sales fell by 35% YoY and by 15% QoQ

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 61% more than the total liabilities
The current ratio has soared by 61% YoY and by 9% from the previous quarter
The total liabilities has grown by 35% YoY and by 2.7% from the previous quarter
The debt is 16% greater than the equity
The debt is up by 48% year-on-year and by 11% since the previous quarter
The debt to equity has grown by 33% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.